Correction: Cell Communication and Signaling (2019) 17:17 https://doi.org/10.1186/s12964-019-0327-5
Following publication of the original article [1], the authors identified that Fig. 5C image was uploaded in error where the original data did not match the uploaded data. We suspect that this error was due to the plate handling. Although the results and conclusion are still the same, we would like to correct this error. The corrected Fig. 5C is presented in this correction article. The authors declare that these corrections do not change the results or conclusions of this paper.
CDK4 inhibition induced by palbociclib suppresses cell migration and invasion. After exposure to 1 µM of palbociclib for the indicated time, the cell migration of CS-1 and SW1353 cells was determined by wound healing assay. A Representative images of CS-1 and SW1353 cell migration after palbociclib treatment for 0, 16, and 32 h (scale bar = 50 μm). B Cell migration distance of CS-1 cells was measured after palbociclib treatment. *P < 0.05 compared with 0 h group. C Human chondrosarcoma cells CS-1 and SW1353 were starved for 12 h, and then seeded in the top chambers of transwells with matrigel in the presence of the indicated doses of palbociclib. The bottom chambers of the transwells were filled with a medium containing 10% FBS. Cancer cells were allowed to invade for 10–12 h. The invading purple-stained cells showing irregular shape were photographed and counted (scale bar = 50 μm). D Quantitative analysis of the percentage of cell invasion using ImageJ. Columns represent the means of experiments performed in triplicate, where the bars represent the SD. **P < 0.01 compared with cell only group
Reference
Ouyang Z, Wang S, Zeng M, et al. Therapeutic effect of palbociclib in chondrosarcoma: implication of cyclin-dependent kinase 4 as a potential target. Cell Commun Signal. 2019;17:17. https://doi.org/10.1186/s12964-019-0327-5.
Author information
Authors and Affiliations
Corresponding authors
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
The online version of the original article can be found at https://doi.org/10.1186/s12964-019-0327-5.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Ouyang, Z., Wang, S., Zeng, M. et al. Correction: therapeutic effect of palbociclib in chondrosarcoma: implication of cyclin-dependent kinase 4 as a potential target. Cell Commun Signal 21, 40 (2023). https://doi.org/10.1186/s12964-023-01046-y
Published:
DOI: https://doi.org/10.1186/s12964-023-01046-y